Skip to content

Genetic Autopsy and Sudden Death

Genetic Autopsy and Sudden Death of Young Subject

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02920203
Acronym
AGEMOS
Enrollment
300
Registered
2016-09-30
Start date
2017-10-11
Completion date
2020-12-31
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden Death

Keywords

Sudden unexpected death, young subjects, molecular genetic autopsy, sequencing

Brief summary

The purpose of the study is to better identify hereditary cardiac causes of sudden unexpected death in young subjects through Next-Generation Sequencing of autopsy tissue

Detailed description

Monitoring : For index cases group, all the data will be monitored. For the relatives group, only the informed consent will be monitored Statistical analysis : * Evaluate the additional elucidation rate of unexpected sudden death * Evaluate causes obtained by Next Generation Sequencing (NGS) ( in comparison with conventional autopsy (macroscopic and / or microscopic) * Descriptive study of the causes of sudden unexpected death, identified hereditary cardiac causes percentages compared via various diagnostic approaches * Cost-effectiveness analysis Data Management : A database is created for the AGEMOS study with control of the discrepancies. All the index cases' data entered in the data base will be double checked

Interventions

GENETICHeart and spleen tissue

genetic sequencing

Sponsors

Pathology department and forensic Institute, Raymond Poincaré hospital, Garches
CollaboratorUNKNOWN
Referal Center for Inherited cardiac diseases, Pitié Salpêtrière Hospital, Paris
CollaboratorUNKNOWN
Pitié-Salpêtrière Hospital
CollaboratorOTHER
Clinical research Unit, Ambroise Paré Hospital, Boulogne Billancourt
CollaboratorUNKNOWN
Cardiogenetic and molecular and cellular myogenetic functionnal unit Pitié Salpêtrière hospital, Paris
CollaboratorUNKNOWN
Molecular and medical Virology Laboratory, Medical School, Reims
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

Index cases : Inclusion Criteria: * Subjects of more than 2 years old and less than 41 years old * Sudden unexpected death from natural and nontraumatic causes * Macroscopic autopsy performed within 72 hours after death and without signs of body decomposition * No extracardiac obvious causes, including toxicological analysis when available * No significant coronary cause after autopsy (such as tight coronary stenosis, congenital abnormality of the arteries, coronary vasculitis) * Informed consent of the close relation (family/reliable person) and / or legal representative Relatives : Inclusion Criteria: * To be a first degree relative (parents, sister, brother, child) of a deceased subject included in the AGEMOS study and accept to perform medical examination and transmit results of examination

Design outcomes

Primary

MeasureTime frameDescription
Comparison of sudden death elucidation rate obtained by high throughput sequencing (NGS) versus conventional autopsy (macroscopic and / or microscopic)27 monthsAim is to determine if elucidation rate of unexpected sudden death causes obtained by high throughput sequencing (NGS) is significantly better than conventional autopsy (macroscopic and / or microscopic) alone. Inclusion of a series of 100 consecutive and exhaustive cases (index cases) recruited by forensic institutes or pathology departements. Determine the rate of sudden death elucidation after NGS (after targeted capturing of 100 genes responsible for inherited cardiac diseases, including cardiomyopathy and electrical diseases) and comparison of sudden death elucidation rate obtained with conventional autopsy (macroscopic and microscopic) by chi 2 analysis.

Secondary

MeasureTime frameDescription
Describe the epidemiology of causes of sudden death27 monthsInclusion of a serie of consecutive and exhaustive subjects recruited by forensic institutes or pathology departements. Determination all the causes of death after conventional autopsy (unnatural, toxicological, non-cardiovascular, vascular, cardiological and coronary, cardiological and non-coronary causes such as cardiomyopathies & myocarditis, no cause identified Descriptive analysis. All quantitative data will be analyzed with the average, standard deviation and median. Frequencies and Clopper-Pearson confidence interval of 95% will be provided
Comparison of elucidation rates of cause of sudden death including systematic cardiac screening in relatives39 monthsAim is to determine the impact of systematic family cardiac screening in the understanding of sudden deaths Comparison of elucidation rates of cause of sudden death according to three methods: i) identification of a hereditary heart disease via the systematic cardiac screening performed in relative; ii) by the conventional autopsy; iii) by sequencing NGS analysis; Statistics: test of McNemar (mated series). The threshold for level of statistical significance is chosen at 5 %.
Medico-economic modeling of the various diagnostic approaches39 monthsCost-effectiveness modeling evaluation of medical and economic impact of the genetic molecular autopsy, efficacy being estimated by years of life saved in the family

Countries

France

Contacts

Primary ContactGeoffroy Lorin de la Grandmaison, Pr
g.lorin@aphp.fr+33(0)1 47 10 76 90
Backup ContactPhilippe Charron, MD, PhD
philippe.charron@aphp.fr+33 (0)1 42 16 13 47

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026